Background: Afatinib, an irreversible ErbB family blocker, significantly improved progression-free survival (PFS) versus platinum-doublet chemotherapy as first-

Background: Many attempts have been described to stablish peripheral blood ratios as systemic immune biomarkers in lung cancer, unfortunately they are not still considered because of lack accuracy and sensibility. In this study, we explore and correlate clinical stages to median values of peripheral blood ratios as Neutrophil-to-lymphocyte ratio (NLR), Monocyte-to-lymphocyte ratio (MLR) and Platelets-tolymphocyte ratio (PLR) among patients with lung cancer. Method: Retrospectively, we review clinical and laboratory data from 193 patients with lung cancer treated at Oncosalud e AUNA from 2011 to 2014. The laboratory data (hemoglobin, leukocytes, neutrophil, lymphocyte and monocyte) were collected from blood routine test obtained from the first clinic visit. The median (range) and mean (± SD) of the ratios were determined according every clinical stage and compared using the U Mann Whitney test. Result: Median age was 67 years, and 63 (

Background: Platinum-based doublets represent standard of care (SoC) first-line treatment for pts with advanced NSCLC.

No abstract